Cargando…

Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas

OBJECTIVE: To identify novel epigenetic signatures that could provide predictive information that is complementary to promoter methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) gene for predicting temozolomide (TMZ) response, among glioblastomas (GBMs) without glioma-CpGs isla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, An-An, He, Ya-Long, Etcheverry, Amandine, Liu, Yu-He, Aubry, Marc, Barnholtz-Sloan, Jill, Liu, Bo-Lin, Mosser, Jean, Lu, Zi-Fan, Zhang, Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515684/ https://www.ncbi.nlm.nih.gov/pubmed/31088577 http://dx.doi.org/10.1186/s13148-019-0670-9

Ejemplares similares

A five‐CpG signature of microRNA methylation in non‐G‐CIMP glioblastoma
por: Kang, En‐Ming, et al.
Publicado: (2019)

A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas
por: Li, Bowen, et al.
Publicado: (2022)

Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas
por: Yin, Anan, et al.
Publicado: (2021)

Integrative analysis of novel hypomethylation and gene expression signatures in glioblastomas
por: Yin, Anan, et al.
Publicado: (2017)

Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas
por: Li, Jie, et al.
Publicado: (2014)

Distinct epigenetic signatures elucidate enhancer-gene relationships that delineate CIMP and non-CIMP colorectal cancers
por: Chong, Allen, et al.
Publicado: (2016)

DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide
por: Etcheverry, Amandine, et al.
Publicado: (2014)

‘From the core to beyond the margin’: a genomic picture of glioblastoma intratumor heterogeneity
por: Aubry, Marc, et al.
Publicado: (2015)

Correction: From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity
por: Aubry, Marc, et al.
Publicado: (2016)

EMT is associated with an epigenetic signature of ECM remodeling genes
por: Peixoto, Paul, et al.
Publicado: (2019)

G-Cimp Status Prediction Of Glioblastoma Samples Using mRNA Expression Data
por: Baysan, Mehmet, et al.
Publicado: (2012)

Immune genes are associated with human glioblastoma pathology and patient survival
por: Vauléon, Elodie, et al.
Publicado: (2012)

The expression of EMX2 lead to cell cycle arrest in glioblastoma cell line
por: Monnier, Annabelle, et al.
Publicado: (2018)

Expression and regulatory roles of lncRNAs in G-CIMP-low vs G-CIMP-high Glioma: an in-silico analysis
por: Datta, Indrani, et al.
Publicado: (2021)

Network Signatures of Survival in Glioblastoma Multiforme
por: Patel, Vishal N., et al.
Publicado: (2013)

18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high
por: Ogino, Shuji, et al.
Publicado: (2007)

DNA methylation in glioblastoma: impact on gene expression and clinical outcome
por: Etcheverry, Amandine, et al.
Publicado: (2010)

EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas
por: Lachat, Camille, et al.
Publicado: (2020)

The CpG island methylator phenotype (CIMP) in colorectal cancer
por: Mojarad, Ehsan Nazemalhosseini, et al.
Publicado: (2013)

Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
por: Gallitto, Matthew, et al.
Publicado: (2020)

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas
por: Cai, Hong-Qing, et al.
Publicado: (2020)

Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions
por: Belter, Agnieszka, et al.
Publicado: (2020)

Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system
por: Bae, Jeong Mo, et al.
Publicado: (2017)

CIMP-positive glioma is associated with better prognosis: A systematic analysis
por: Xu, Yingying, et al.
Publicado: (2022)

Comment on ‘Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system’
por: Tapial, Sandra, et al.
Publicado: (2018)

Unique characteristics of CpG island methylator phenotype (CIMP) in a Chinese population with colorectal cancer
por: Liu, Jiang, et al.
Publicado: (2019)

Reply to ‘Comment on ‘Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system”
por: Bae, Jeong Mo, et al.
Publicado: (2018)

Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
por: He, Yang, et al.
Publicado: (2019)

The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation
por: Miller, Brendan F., et al.
Publicado: (2016)

Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme
por: Cheray, Mathilde, et al.
Publicado: (2020)

Treatment and surgical factors associated with longer-term glioblastoma survival: a National Cancer Database study
por: Malay, Sindhoosha, et al.
Publicado: (2020)

HOXD‐AS2‐STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma
por: Zhang, Zuo‐Xin, et al.
Publicado: (2023)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Identification of Key Candidate Proteins and Pathways Associated with Temozolomide Resistance in Glioblastoma Based on Subcellular Proteomics and Bioinformatical Analysis
por: Yi, Guo-zhong, et al.
Publicado: (2018)

Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma
por: Li, Ganxun, et al.
Publicado: (2019)

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival
por: Gittleman, Haley, et al.
Publicado: (2019)

Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line
por: Barciszewska, Anna-Maria, et al.
Publicado: (2023)

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status
por: Wu, Qiong, et al.
Publicado: (2023)

Coixendide efficacy in combination with temozolomide in glioblastoma and transcriptome analysis of the mechanism
por: Zhao, Zhenran, et al.
Publicado: (2023)

Body Size, Physical Activity and Risk of Colorectal Cancer with or without the CpG Island Methylator Phenotype (CIMP)
por: Hughes, Laura A. E., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4f2v7cnie0f54hqb1p75u20e65